Zydus Lifesciences

Zydus Lifesciences has secured approval from the U.S. Food and Drug Administration (USFDA) for its latest antihypertensive drug, marking a strategic milestone in the company’s global expansion plans. The approval allows Zydus to market the medication in the highly regulated U.S. pharmaceutical market, expanding its portfolio in cardiovascular therapies. Industry experts view this development as a significant opportunity for revenue growth and international market penetration, reflecting Zydus’ commitment to innovation, regulatory compliance, and global standards.

Zydus Lifesciences has received final approval from the U.S. Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) to manufacture and market sacubitril and valsartan tablets in the American market. This medication, widely prescribed for treating heart failure, is a generic version of the blockbuster brand Entresto®. The approval strengthens Zydus’s U.S. portfolio and expands its footprint in the high-demand cardiovascular therapeutics space.